Ran Reshef

8.5k citations

140 papers · 2.3k indexed · h-index 27

Hematology top 1%
- Hematopoietic Stem Cell Transplantation 41
Transplantation top 2%
- Renal Transplantation Outcomes and Treatments 13
Oncology top 2%
- CAR-T cell therapy research 41
- Viral-associated cancers and disorders 24
- Polyomavirus and related diseases 18
Immunology top 5%
- Immune Cell Function and Interaction 18
Pathology and Forensic Medicine top 5%
- Lymphoma Diagnosis and Treatment 24
Genetics
- Chronic Lymphocytic Leukemia Research 13

Co-authors: David Porter Edward A. Stadtmauer Daniel F. Heitjan Robert H. Vonderheide Marlise R. Luskin Elizabeth O. Hexner Donald E. Tsai Noelle V. Frey
Cited by: Hematology Transplantation Oncology
Journals: Blood (33 papers)Biology of Blood and Marrow Transplantation (20 papers)Journal of Clinical Oncology (13 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Ran Reshef

128 papers receiving 2.2k citations

Peers

Countries citing papers authored by Ran Reshef

Since Specialization

Citations

This map shows the geographic impact of Ran Reshef's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ran Reshef with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ran Reshef more than expected).

Fields of papers citing papers by Ran Reshef

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ran Reshef. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ran Reshef. The network helps show where Ran Reshef may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ran Reshef, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ran Reshef Line = papers co-authored together Ran Reshef links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Surviving Grade 4 ICANS: A Case Report and Discussion of Emerging Management Strategies Journal of Child Neurology ·G Mandhal-Barth,Z. Xia,P. Vohrioger,Shu-Ying Deng,Ran Reshef,秀策諏訪	2025	1
2	Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein–Barr Virus–Driven Posttransplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy Transplantation and Cellular Therapy ·Armin Ghobadi,Robert A. Baiocchi,Roselyne de Villanova,Sridhar Chaganti,Sylvain Choquet,Şakir Cəfərov,Rajani Dinavahi,Elisabeth Petit,Laurence Gamelin,Kris M. Mahadeo,Aditi Mehta,Sarah Nikiforow,Ran Reshef,鍋島佑基,Chang-Zhen Wu,Susan E. Prockop	2025	0
3	TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910) Transplantation and Cellular Therapy ·Monzr M. Al Malki,Alla Keyzner,Jas. J. King,Yibin Chen,Hyung C. Suh,Tania Jain,Melhem Solh,Anson Snow,Luis Piñeiro,Saar Gill,Lohith Gowda,Joseph P. Uberti,Timothy P. White,Yun Wang,Cuong V. Nguyen,Chrystal U. Louis,Shrikanta Chattopadhyay,Michelle Matzko,Ran Reshef	2025	0
4	Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report Frontiers in Oncology ·Aldana Cerda Lizbeth Guadalupe,Héctor Raúl Ibarra‐Sifuentes,Mark N. Stein,G. O. Wornson,Markus Y. Mapara,Céline Jacquemont,Ran Reshef	2025	0
5	A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Journal of Clinical Oncology ·Monzr M. Al Malki,Alla Keyzner,Hyung C. Suh,Uday Popat,Saar Gill,Демьяненко Светлана Геннадьевна,Melhem Solh,Lohith Gowda,Erica L. Buonomo,Yun Wang,J. A. H. Murray,Gavin MacBeath,Débora Barton,Shrikanta Chattopadhyay,Ran Reshef	2024	1
6	High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemia Blood ·Éric Durot,Damien Roos‐Weil,Adrien Chauchet,Justine Decroocq,Roberta Di Blasi,Thomas Gastinne,Safira Fadhilla,Morgane Cheminant,Ren Tan Jun,Stéphanie Guidez,François‐Xavier Gros,Emmanuel Bachy,Faik Reşit Unat,Pascale Cony‐Makhoul,Steven P. Treon,Alain Delmer,Ran Reshef,Steven Le Gouill,Jorge J. Castillo,Roch Houot	2024	3
7	Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol Blood Advances ·Sarah Nikiforow,Jennifer Whangbo,Ran Reshef,Donald E. Tsai,Nancy Bunin,Rolla Abu‐Arja,Kris M. Mahadeo,Wen‐Kai Weng,Koen van Besien,David M. Loeb,Sunita D. Nasta,Eneida R. Nemecek,Hans Michael Huck,Yan Sun,Jean N Labeque,Justin T. Wahlstrom,Aditi Mehta,Laurence Gamelin,Rajani Dinavahi,Susan E. Prockop	2024	8
8	Novel Risk Factors for Predicting Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS) (P3-14.001) Neurology ·艾克蕙,Roger Hulstein,Gurappa Puttanna Gururaj,Ran Reshef,Marek Spriestersbach	2024	0
9	Remission of lymphoma and rheumatoid arthritis following anti-CD19 chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma Lara D. Veeken ·M RAULLI,Jason Liebowitz,Ran Reshef,Joan M. Bathon	2024	2
10	Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD Blood ·Suzy O'Brien,Shan He,László,Tien D. Bui,Yuanyuan Tian,Rashit B. Idrisov,Yan Zhou,Xin Zhao,Kris Shewmake,Ashish Kumar Jha,Mimi Chen,Tsvetan Penev,Jozef Madžo,Jean‐Pierre J. Issa,Elizabeth O. Hexner,David L. Wiest,Ran Reshef,Hai‐Hui Xue,Yi Zhang	2023	6
11	Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11 Clinical Cancer Research ·Michael D. Jain,David B. Miklos,Caron A. Jacobson,John M. Timmerman,J. L. Morrill,Anthony Kelechi Nwangwu,Xiang Fang,Ankit Patel,Madison Davis,Darren Heeke,剛小林,Mike Mattie,Frank Neumann,Jenny Kim,陈建秋,Simone Filosto,Ran Reshef	2023	6
12	Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory  CD19 expressing hematologic malignancies (NCT05665062) Cancer Research ·Maria Lia Palomba,Matthew Mei,Paolo F. Caimi,MAYKON V. SILVA,Marco L. Davila,Chee Kong Wong,Kimberly Kluglein,Matias Lehtinen,Martin Oft,Paul‐Joseph Aspuria,Октавија Неделку,Navneet Ratti,Naiyer A. Rizvi,Kelsey M. Thomas,Ran Reshef	2023	3
13	Reduced Early Mortality with Daratumumab-Based Frontline Therapy in Systemic AL Amyloidosis- Experience from the Columbia Amyloidosis Multidisciplinary Program Blood ·Rajshekhar Chakraborty,Divaya Bhutani,Markus Y. Mapara,Ran Reshef,Mathew S. Maurer,Jai Radhakrishnan,Suzanne Lentzsch	2023	1
14	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study Journal of Clinical Oncology ·Ran Reshef,Wael Saber,Javier Bolaños‐Meade,George Chen,Yi‐Bin Chen,Vincent T. Ho,Doris M. Ponce,Ryotaro Nakamura,Michael J. Martens,John A. Hansen,John E. Levine	2021	15
15	Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) Blood ·Susan E. Prockop,Kris M. Mahadeo,Amer Beitinjaneh,Sylvain Choquet,Patrick J. Stiff,Ran Reshef,Gowri Satyanarayana,Saurabh Dahiya,Hema Parmar,Wei Ye,Laurence Gamelin,Rajani Dinavahi	2021	8
16	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation Journal of Clinical Oncology ·Neema P. Mayor,Tao Wang,Stephanie J. Lee,Michelle Kuxhausen,Cynthia Vierra‐Green,Dominic J. Barker,Jeffery J. Auletta,Vijaya Raj Bhatt,Shahinaz M. Gadalla,Loren Gragert,Yoshihiro Inamoto,Gerald P. Morris,Sophie Paczesny,Ran Reshef,Olle Ringdén,Bronwen E. Shaw,Peter J. Shaw,Stephen R. Spellman,Steven G. E. Marsh	2021	27
17	Baloxavir treatment of oseltamivir‐resistant influenza A/H1pdm09 in two immunocompromised patients Transplant Infectious Disease ·Nenad Maćešić,Jennifer Laplante,Justin G. Aaron,Emily DiMango,Benjamin A. Miko,Marcus R. Pereira,Ran Reshef,Kirsten St. George	2020	10
18	Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder Biology of Blood and Marrow Transplantation ·Susan E. Prockop,Tsungying Yang,Robert A. Baiocchi,Nancy Bunin,Kris M. Mahadeo,Eneida R. Nemecek,Sarah Nikiforow,Ran Reshef,Donald E. Tsai,Willis H. Navarro,Richard J. O’Reilly	2018	6
19	Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies Blood ·Gurappa Puttanna Gururaj,Dale Crossman,金河龍,李达祥,Amer Assal,Markus Y. Mapara,Ran Reshef	2017	1
20	Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation Clinical Cancer Research ·Gregory L. Beatty,Jasmine S. Smith,Ran Reshef,Kunal P. Patel,Theresa A. Colligon,Barbara A. Vance,Noelle V. Frey,F. Brad Johnson,David L. Porter,Robert H. Vonderheide	2009	36

About Ran Reshef

Ran Reshef is a scholar working on Transplantation, Hematology, Oncology, Immunology and Genetics, having authored 140 papers that have together received 2.3k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (41 papers), CAR-T cell therapy research (41 papers), Viral-associated cancers and disorders (24 papers), Lymphoma Diagnosis and Treatment (24 papers), Polyomavirus and related diseases (18 papers), Immune Cell Function and Interaction (18 papers), Renal Transplantation Outcomes and Treatments (13 papers) and Chronic Lymphocytic Leukemia Research (13 papers). The work is most often cited by research in Hematology (660 citations), Transplantation (137 citations), Oncology (995 citations), Immunology (635 citations) and Pathology and Forensic Medicine (361 citations). Ran Reshef has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include David Porter, Edward A. Stadtmauer, Daniel F. Heitjan, Robert H. Vonderheide, Marlise R. Luskin, Elizabeth O. Hexner, Donald E. Tsai, Noelle V. Frey, Alison W. Loren and Selina M. Luger. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Journal of Clinical Oncology, Transplantation and Cellular Therapy and American Journal of Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact